Highlights
- Market Cap
- $278.75M
- Enterprise Value
- -$91.65M
- EPS (TTM)
- -$5.14
- EBITDA (TTM)
- -$166.12M
- Year Range
- $8.51 - $14.87
- Target Price
- $23.40
- ROA (TTM)
- -29.90%
- ROE (TTM)
- -32.61%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in BridgeBio Oncology Therapeutics, Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
BridgeBio Oncology Therapeutics, Inc
- 1D
- 3.11%
- 1M
- -10.77%
- YTD
- -28.51%
- 6M
- -22.71%
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Aug 12, 2025, BBOT's average daily return is +0.06%, while the average monthly return is -0.19%.
Historically, 50% of months were positive and 50% were negative. The best month was Sep 2025 with a return of +29.5%, while the worst month was Feb 2026 at -14.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 3 months.
On a daily basis, BBOT closed higher 46% of trading days. The best single day was Dec 5, 2025 with a return of +18.6%, while the worst single day was Aug 19, 2025 at -15.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -6.39% | -14.42% | -10.77% | -28.51% | |||||||||
| 2025 | -7.36% | 29.53% | 3.11% | 3.10% | 1.71% | 29.74% |
Benchmark Metrics
BridgeBio Oncology Therapeutics, Inc has an annualized alpha of 12.99%, beta of 1.38, and R² of 0.05 versus S&P 500 Index. Calculated based on daily prices since August 13, 2025.
- This stock participated in 291.67% of S&P 500 Index downside but only 272.08% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.05 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 12.99%
- Beta
- 1.38
- R²
- 0.05
- Upside Capture
- 272.08%
- Downside Capture
- 291.67%
Return for Risk
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for BridgeBio Oncology Therapeutics, Inc (BBOT) and compare them to a chosen benchmark (S&P 500 Index).
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the BridgeBio Oncology Therapeutics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the BridgeBio Oncology Therapeutics, Inc was 36.78%, occurring on Mar 30, 2026. The portfolio has not yet recovered.
The current BridgeBio Oncology Therapeutics, Inc drawdown is 34.81%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -36.78% | Nov 18, 2025 | 90 | Mar 30, 2026 | — | — | — |
| -26.82% | Aug 19, 2025 | 4 | Aug 22, 2025 | 20 | Sep 22, 2025 | 24 |
| -15.72% | Oct 7, 2025 | 12 | Oct 22, 2025 | 13 | Nov 10, 2025 | 25 |
| -6.99% | Sep 23, 2025 | 1 | Sep 23, 2025 | 7 | Oct 2, 2025 | 8 |
| -2.9% | Nov 12, 2025 | 2 | Nov 13, 2025 | 1 | Nov 14, 2025 | 3 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of BridgeBio Oncology Therapeutics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how BridgeBio Oncology Therapeutics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BBOT in comparison with other companies in the Biotechnology industry. Currently, BBOT has a P/B value of 0.7. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |